twitter

Tuesday, 8 November 2016

Ethanol in herbal medicinal products for children : Data from pediatric studies and pharmacovigilance programs.

2016 Jul 28. [Epub ahead of print]

Author information

  • 1Board of the Corporative Members, Gesellschaft für Phytotherapie e. V. (GPT), Cologne, Germany. olaf.kelber@bayer.com.
  • 2Innovation & Development, Phytomedicines Supply and Development Center, Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH, Havelstr. 5, 64295, Darmstadt, Germany. olaf.kelber@bayer.com.
  • 3Board of the Corporative Members, Gesellschaft für Phytotherapie e. V. (GPT), Cologne, Germany.
  • 4Bundesverband der Arzneimittel-Hersteller, Bonn, Germany.
  • 5Cassella-med GmbH & Co. KG, Cologne, Germany.
  • 6Dr. Loges + Co. GmbH, Winsen, Germany.
  • 7Institute for Integrative Medicine Siegen, Siegen, Germany.
  • 8Medical Affairs, Phytomedicines Supply and Development Center , Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH , Darmstadt, Germany.
  • 9Chair of Complementary Medicine, Center of Internal Medicine, Universitätsmedizin Rostock, Rostock, Germany.
  • 10Scientific Board, Gesellschaft für Phytotherapie e. V. (GPT), Cologne, Germany.
  • 11Institute of Pharmacy, University of Leipzig, Leipzig, Germany.

Abstract

Herbal medicinal products are indispensable in children, e. g., in functional gastrointestinal diseases and coughs and colds, especially when available in liquid dosing forms for which dosing can be adapted ideally to different age groups. Despite being generally accepted as safe, the ethanol content of many of these products, necessary for Galenic reasons, has raised questions regarding their safety. Therefore, safety data from more than 50,000 children in noninterventional pediatric studies with these products, as well as data from routine clinical use in several million children, were assessed. No evidence of the involvement of the ethanol content in any adverse drug reactions was found. This allows us to conclude that these herbal medicinal products are safe in the age groups for which they are authorized or registered and that the present labeling is adequate to allow for their safe use in the pediatric population.

KEYWORDS:

Benefit–risk assessment; Labeling; Liquid dosing form; Pediatric medicinal product; Phytotherapy
PMID:
27468971
DOI:
10.1007/s10354-016-0474-x